Actinium Pharmaceuticals, Inc.
ATNM
$1.26
$0.1614.55%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.42% | -45.74% | -26.97% | 201.76% | 16.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.54% | -54.11% | -39.58% | 73.37% | -28.00% |
| Operating Income | 14.54% | 54.83% | 39.58% | -73.37% | 27.44% |
| Income Before Tax | 10.70% | 55.64% | 39.42% | -83.83% | 28.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.70% | 55.64% | 39.42% | -83.83% | 28.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.70% | 55.64% | 39.42% | -83.83% | 28.66% |
| EBIT | 14.54% | 54.83% | 39.58% | -73.37% | 27.44% |
| EBITDA | 14.56% | 55.75% | 40.31% | -75.17% | 27.57% |
| EPS Basic | 10.69% | 55.82% | 41.53% | -64.33% | 37.28% |
| Normalized Basic EPS | 10.66% | 55.82% | 41.54% | -64.33% | 37.32% |
| EPS Diluted | 10.69% | 55.82% | 41.53% | -64.33% | 37.28% |
| Normalized Diluted EPS | 10.66% | 55.82% | 41.54% | -64.33% | 37.32% |
| Average Basic Shares Outstanding | -0.03% | 0.40% | 3.63% | 11.87% | 13.77% |
| Average Diluted Shares Outstanding | -0.03% | 0.40% | 3.63% | 11.87% | 13.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |